CRDF News and Press, Cardiff Oncology Inc. From 09/27/23

2023-09-27 07:42:23 ET (24/7 MARKET NEWS) – Cardiff Oncology, Inc. (NASDAQ: CRDF) reported, after yesterday’s market close, positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma (mPDAC) ...

2023-09-27 05:47:01 ET Related stories MillerKnoll, Inc. (MLKN) Q1 2024 Earnings Call Transcript MillerKnoll Stock: On A Roll Cardiff Oncology (CRDF) Investor Presentation - Slideshow Connecting The Dots: Markets React To Hawkish Revisions In The Fed's Intere...

2023-09-26 17:05:11 ET More on Cardiff Oncology Cardiff Oncology: How The Recommitment Shapes The Investment Thesis (Rating Upgrade) Cardiff Oncology soars as Pfizer backs lead program Seeking Alpha's Quant Rating on Cardiff Oncology For further details see: ...

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy PR Newswire Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-li...

2023-08-14 03:17:14 ET Summary Cardiff Oncology stock has recently rallied to around $2 per share after positive guidance from the FDA on a regulatory path forward for their PLK1 inhibitor. The company plans to initiate a trial called CRDF-004, a randomized study assessing onvanse...

2023-08-09 17:28:22 ET Cardiff Oncology press release ( NASDAQ: CRDF ): Q2 GAAP EPS of -$0.25 beats by $0.01 . Revenue of $0.11M (+22.2% Y/Y) beats by $0.05M . Cash, cash equivalents, and short-term investments of approximately $89.4 million as of June 30, 2023...

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update PR Newswire - New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 - - Advance to fir...

2023-08-09 08:45:56 ET Palm Beach, FL – August 9, 2023 – FinancialNewsMedia.com News Commentary – About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group thereby creating the de...

2023-08-08 12:46:20 ET Gainers: Infinity Pharmaceuticals ( INFI ) +56% . Bright Minds Biosciences ( DRUG ) +46% . Tilray Brands ( TLRY ) +31% . Paymentus Holdings (PAY) +33% . Gorilla Technology Group ( GRRR ) +28% . Cardiff Onco...

2023-08-08 12:45:03 ET More on Pfizer Pfizer Inc. ( PFE ) Q2 2023 Earnings Call Transcript How Pfizer Stands In My Investment Plans For Our Dividend Growth Portfolio Pfizer: Significant Plunge, Offering Exceptional Buying Opportunity Pfizer: A 4.5% Divide...